AMJ Podcast | Episode 8 | Real-World Insights into Biologic Initiation and Adherence in Severe Asthma Inside

This podcast was developed by AMJ in collaboration with GSK and is sponsored by GSK. This information is scientific and non-promotional in nature, and intended for US audiences.   Less than 20% of biologic-eligible patients with GINA Step 5 asthma receive biologic therapy.1,2 In this AMJ podcast, experts discuss how real-world gaps in initiation, access, and adherence can affect whether patients start, stay on, and sustain benefit from biologic therapy over time.   Listen to the full episode to explore: Key real-world data on biologic initiation and adherence in severe asthma Patient cases showing common barriers across the care pathway Practical ways to uncover the burden of severe asthma The Start, Stay, Sustain framework for patient-centered care   Speakers: Justin Kwiatek, US Medical Affairs Lead, Respiratory Biologics, GSK Tom Corbridge, US Senior Medical Director, Respiratory Biologics, GSK   References Park J et al. Biologic underutilization and healthcare burden in US patients with Type 2 severe asthma. J Asthma Allergy. 2026;19:580937. Maselli DJ et al. Patient characteristics and social determinants of health influence adherence to biologic therapy for asthma. SEAAIS 80th Annual Meeting, October 23-26, 2025.